Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Upgraded by TD Cowen

Kymera Therapeutics (NASDAQ:KYMR) was upgraded by investment analysts at TD Cowen to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Several other research firms have also commented on KYMR. Oppenheimer reissued an “outperform” rating and issued a $125.00 price objective on shares of Kymera Therapeutics in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Friday, July 17th. Deutsche Bank Aktiengesellschaft started coverage on Kymera Therapeutics in a research note on Thursday, July 30th. They issued a “hold” rating and a $120.00 target price for the company. B. Riley Financial raised their target price on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Mizuho boosted their price target on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $125.65.

Kymera Therapeutics Trading Up 1.0%

Shares of KYMR stock opened at $121.05 on Monday. The company’s fifty day simple moving average is $110.13 and its 200-day simple moving average is $92.46. Kymera Therapeutics has a 52 week low of $39.84 and a 52 week high of $130.05. The company has a market cap of $10.07 billion, a PE ratio of -37.36 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm had revenue of $65.00 million during the quarter, compared to analysts’ expectations of $32.78 million. During the same period in the prior year, the company earned ($0.95) EPS. The firm’s revenue was up 465.2% on a year-over-year basis. Equities research analysts expect that Kymera Therapeutics will post -3.75 EPS for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In related news, insider Noah Goodman sold 3,389 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $114.29, for a total value of $387,328.81. Following the sale, the insider directly owned 47,179 shares of the company’s stock, valued at $5,392,087.91. This represents a 6.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Nello Mainolfi sold 50,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the chief executive officer owned 666,568 shares in the company, valued at approximately $79,321,592. This trade represents a 6.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 3,591,908 shares of company stock valued at $386,532,863. Corporate insiders own 15.98% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of KYMR. Smartleaf Asset Management LLC increased its holdings in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after acquiring an additional 424 shares during the last quarter. Larson Financial Group LLC lifted its stake in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the last quarter. Osaic Holdings Inc. lifted its stake in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after purchasing an additional 98 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics in the fourth quarter worth $63,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.